Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - The lawsuit alleges that Inspire misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand due to excess inventory of older devices [7]. - Following this announcement, Inspire's stock price fell by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, with a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year [5]. - Following the announcement of these results, CarMax's stock price dropped by $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 2025 outlook, led to an additional stock price drop of over 24% [6]. Group 3: Market Context - CarMax's previous claims of strong demand were allegedly inflated due to a temporary boost from U.S. tariffs on cars, which prompted customers to purchase vehicles before the tariffs took effect [3]. - The lawsuit also investigates whether CarMax properly assessed or reserved for its portfolio of car loans following the CEO's departure [4].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the United States and Canada [4]. Allegations and Stock Impact - The lawsuit claims that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, attributing sales to sustainable customer demand rather than inventory loading by channel partners, which is characterized as fraudulent channel stuffing [5]. - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, leading to a stock price drop of $9.79 per share, or over 34%, from $28.43 to $18.64 [6]. Legal Proceedings - Investors have until December 23, 2025, to request to lead the case in the U.S. District Court for the Northern District of Illinois, with the case titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al. [3].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to significant delays in adoption [5][6]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Freeport-McMoRan Inc. is a mining company with its Indonesian affiliate operating as PT Freeport Indonesia, which manages the Grasberg Copper and Gold Mine [4]. Allegations - The lawsuit alleges that Freeport overstated its commitment to safety, as unsafe mining practices at the Grasberg mine were likely to result in worker fatalities [5]. Stock Performance Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) after announcing the suspension of mining operations due to a landslide that trapped seven team members [6]. - Following an update on September 24, 2025, which reported two fatalities and five missing individuals, the stock fell by $7.69 per share (almost 17%) [7]. - On September 25, 2025, news regarding strained relations with the Indonesian government led to a further decline of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, indicated that the landslide was preventable, further impacting investor sentiment [9].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Impact - On October 23, 2025, Integer revised its 2025 sales guidance downward to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Baxter International, Inc. is facing a securities fraud class action lawsuit due to serious safety issues related to its Novum IQ Large Volume Pump, which has been linked to patient injuries and deaths, leading to a significant drop in stock price [1][4][5]. Group 1: Incident Overview - On April 7, 2025, a Missouri news outlet reported safety issues with Baxter's Novum LVP, claiming it was unsafe for patient treatment based on a whistleblower's information [2]. - Baxter issued warning letters on April 24 and July 14, 2025, regarding underinfusion and overinfusion risks, revealing 79 reports of serious injuries and two patient deaths associated with the device [3]. - The FDA classified the issues with Novum LVP as a Class I recall, indicating a severe risk of injury or death [3]. Group 2: Stock Impact - Following the announcement of a voluntary pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's stock price fell by $6.24, or 22.4%, closing at $21.61 per share [4]. Group 3: Lawsuit Details - The lawsuit alleges that Baxter made false or misleading statements regarding the safety and functionality of the Novum LVP, failing to disclose systemic defects and the risks associated with the device [5]. - It is claimed that Baxter was aware of multiple malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [5].

Core Viewpoint - DeFi Technologies Inc. is facing significant legal challenges following a decline in stock price due to disappointing financial results and operational issues related to its arbitrage trading strategy [1][3][5]. Group 1: Financial Performance - On November 6, 2025, DeFi reported that its digital asset treasuries had absorbed or delayed a significant share of arbitrage opportunities, leading to a stock price drop of $0.13, or 7.4%, closing at $1.62 per share [2]. - The company subsequently reported a nearly 20% revenue decline in its third quarter 2025 results and significantly lowered its 2025 revenue forecast, attributing this to delays in executing its arbitrage strategy and increased competition [3]. - Following the financial results announcement, DeFi's stock price fell by $0.40, or 27.6%, over two trading days, closing at $1.05 per share [4]. Group 2: Legal Action - A class action lawsuit has been filed on behalf of investors who purchased DeFi securities during the class period from May 12, 2025, to November 14, 2025, alleging that the company made materially false and misleading statements regarding its business and financial prospects [1][5]. - The lawsuit claims that DeFi failed to disclose delays in its arbitrage strategy, underestimated competition from other digital asset trading companies, and downplayed the negative impact of these issues on its financial results [5]. - Investors are reminded of the January 30, 2026, deadline to file a lead plaintiff motion in this class action [1][6].

BENSALEM, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Sprouts Farmers Market, Inc. (“Sprouts” or the “Company”) (NASDAQ: SFM) securities between June 4, 2025 and October 29, 2025, inclusive (the “Class Period”). Sprouts investors have until January 26, 2026 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SPROUTS (SFM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH T ...

B. Riley Financial offices in Westwood. (Jason Armond / Los Angeles Times) Businessman Brian Kahn has pleaded guilty to conspiracy to commit securities fraud in a case that brought down a hedge fund, helped lead to the bankruptcy of a retailer and damaged West Los Angeles investment bank B. Riley Financial. Kahn, 52, admitted in a Trenton, N.J., federal court Wednesday to hiding trading losses that brought down Prophecy Asset Management in 2020. The Securities and Exchange Commission alleged the losses e ...